These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33414428)

  • 1. A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature.
    El-Sahli S; Hua K; Sulaiman A; Chambers J; Li L; Farah E; McGarry S; Liu D; Zheng P; Lee SH; Cui J; Ekker M; Côté M; Alain T; Li X; D'Costa VM; Wang L; Gadde S
    Cell Death Dis; 2021 Jan; 12(1):8. PubMed ID: 33414428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-targeting Bulk Tumor and CSCs in Clinically Translatable TNBC Patient-Derived Xenografts via Combination Nanotherapy.
    Sulaiman A; McGarry S; El-Sahli S; Li L; Chambers J; Phan A; Côté M; Cron GO; Alain T; Le Y; Lee SH; Liu S; Figeys D; Gadde S; Wang L
    Mol Cancer Ther; 2019 Oct; 18(10):1755-1764. PubMed ID: 31308079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting CD73 with flavonoids inhibits cancer stem cells and increases lymphocyte infiltration in a triple-negative breast cancer mouse model.
    Mediratta K; El-Sahli S; Marotel M; Awan MZ; Kirkby M; Salkini A; Kurdieh R; Abdisalam S; Shrestha A; Di Censo C; Sulaiman A; McGarry S; Lavoie JR; Liu Z; Lee SH; Li X; Sciumè G; D'Costa VM; Ardolino M; Wang L
    Front Immunol; 2024; 15():1366197. PubMed ID: 38601156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells.
    Sulaiman A; McGarry S; Lam KM; El-Sahli S; Chambers J; Kaczmarek S; Li L; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Liu S; Xie Y; Gadde S; Li X; Wang L
    Cell Death Dis; 2018 Jul; 9(8):815. PubMed ID: 30050079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states.
    Sulaiman A; McGarry S; Li L; Jia D; Ooi S; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Gadde S; Li X; Wang L
    Mol Oncol; 2018 Apr; 12(4):423-440. PubMed ID: 29316250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
    Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer.
    Fu S; Chen X; Lo HW; Lin J
    Cancer Lett; 2019 Apr; 448():11-19. PubMed ID: 30707920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
    Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
    Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
    Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
    Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
    Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T
    Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer.
    Jiang C; Wang X; Teng B; Wang Z; Li F; Zhao Y; Guo Y; Zeng Q
    ACS Appl Mater Interfaces; 2021 Aug; 13(30):35248-35265. PubMed ID: 34284582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of inhibitor of yes-associated protein 1 in triple-negative breast cancer with taxol-based chemoresistance.
    Li Y; Wang S; Wei X; Zhang S; Song Z; Chen X; Zhang J
    Cancer Sci; 2019 Feb; 110(2):561-567. PubMed ID: 30467925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albumin Nanoparticle of Paclitaxel (Abraxane) Decreases while Taxol Increases Breast Cancer Stem Cells in Treatment of Triple Negative Breast Cancer.
    Yuan H; Guo H; Luan X; He M; Li F; Burnett J; Truchan N; Sun D
    Mol Pharm; 2020 Jul; 17(7):2275-2286. PubMed ID: 32485107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting the proliferation, migration and invasion of triple negative breast cancer cells through anti-tumor human serum albumin nanoparticles loading aziditaxel as a novel taxane derivative.
    Chen LQ; Zhang ZM; Huang W; Gao ZG; Fang WS; Jin MJ; Yu L
    Pharmazie; 2017 Mar; 72(3):152-160. PubMed ID: 29442050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2 regulates paclitaxel resistance in triple negative breast cancers.
    Han J; Yun J; Quan M; Kang W; Jung JG; Heo W; Li S; Lee KJ; Son HY; Kim JH; Choi J; Noh DY; Na D; Ryu HS; Lee C; Kim JI; Moon HG
    J Mol Med (Berl); 2021 Dec; 99(12):1783-1795. PubMed ID: 34626199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceritinib is a novel triple negative breast cancer therapeutic agent.
    Dong S; Yousefi H; Savage IV; Okpechi SC; Wright MK; Matossian MD; Collins-Burow BM; Burow ME; Alahari SK
    Mol Cancer; 2022 Jun; 21(1):138. PubMed ID: 35768871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer.
    Yuan Z; Jiang H; Zhu X; Liu X; Li J
    Biomed Pharmacother; 2017 May; 89():227-232. PubMed ID: 28231544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.